Houston, Texas (PRWEB) December 20, 2012
The National Eagles and Angels Association (NEAA) held its past meeting in Dallas, Texas. InterlinkedTV has exclusive coverage of the interviews of companies that presented at that event.
Drew Diaz, CEO of Heart Test Laboratories, Inc. granted an Exclusive Interview for Interlinked and InterlinkedTV during the last National Eagles and Angles Association (NEAA) Meeting during which he discussed the company’s early Heart Disease detection capability. In the interview, Drew Diaz explains how heart disease affects people of all ages, and that their product is helping doctors diagnose heart disease early to prevent heart attacks.
"A lot of people are walking around that look good and feel good, asymptomatic. They go visit their doctor, they are told by their doctor that they can go home because they just had an ECG test or physical and they have a heart attack 6 months later. This technology is really geared for the front-side of medicine; for those doctors that are seeing all these patients every day for their annual physical and their checkups." Diaz said "Everywhere where there is an ECG device, there should be a MyoVista device to properly screen both young and older patients."
Heart Test Laboratories Inc.'s patent pending product will replace the 100 year old ECG that is prevalent in all doctors’ offices. The market for their product in 2012 is estimated to be $4 billion dollars.
"I remember getting a call from the hospital that my father had dropped at an airport at 55 from a heart attack. He had just had a checkup and his ECG (EKG) was perfect. I like so many other people wonder could this have been detected or prevented? I have been following Drew Diaz and this company for over 3 years now and believe they have a solution to early detection of heart disease. I have watched this management team build and develop a solution that truly helps us all.” President and CEO of Interlinked, Delray Wannemacher
About Heart Test Laboratories Inc. (HTL) & InterlinkedTV
Heart Test Laboratories Inc., a US based company, is a rapidly developing medical technology company concentrating on inventing life saving devices for the Coronary Arterial Disease (CAD) market. Heart Test Laboratories is in the final stages of releasing it’s new patent pending screening device, the MyoVista, a portable, inexpensive, diagnostic test used to determine the presence and level of myocardial abnormalities and the obstruction of coronary arteries. Since 2003, over 50,000 patients have been correlated with the MyoVista Technology to determine the presence and level of myocardial abnormalities (restriction of blood flow to the heart) through a quick, inexpensive, non-invasive procedure. Two recently completed clinical studies show an average 90% or better correlation to an invasive Coronary Angiogram, indicating this unique technology is positioned to change the way all patients are screened for Coronary Arterial Disease.
InterlinkedTV is an internet video production and distribution site dedicated to Entrepreneurs and Investors. We feature education, public and private companies, venture capital news, and investment events. This content is exclusive and cannot be found anywhere else. We give our members and viewers a unique chance to meet the CEOs and executives of high growth companies. For more information, visit our Web Channel.
Read the full story at http://www.prweb.com/releases/2012/12/prweb10250002.htm.
Copyright©2012 Vocus, Inc.
All rights reserved